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We report the epidemiologic characteristics of
Crimean-Congo hemorrhagic fever in Bulgaria, as well as
the first genetic characterization of the virus strains circulat-
ing in the country in 2002 to 2003 that caused disease in
humans.
C
rimean-Congo hemorrhagic fever virus (CCHFV)
(genus  Nairovirus, family  Bunyaviridae) causes
severe disease with a fatality rate as high as 30%. CCHFV
is endemic in the Balkan Peninsula; a number of cases
occur every year, sometimes in an epidemic form. Cases
have been reported in Albania (1), Kosovo (2,3), and
Bulgaria (4). Mountains approximately 1,500 m to 2,500
m high separate these countries from Greece, where no
case of the disease has yet been identified. However, a
CCHFV strain was isolated in Greece from Rhipicephalus
bursa ticks, collected in May 1975 from goats of a flock in
Vergina village, 80 km west of Thessaloniki (5).
Antibodies against the virus were detected in the Greek
human population (6). CCHFV is also endemic in Russia
and in parts of Asia and Africa. 
The virus is transmitted to humans by the bite of ixodid
ticks (primarily of the Hyalomma  genus) or by contact
with blood or tissues from infected persons or infected
livestock. The risk for spread of the virus from person to
person is high, which occasionally results in nosocomial
outbreaks. After an incubation period of 3 to 7 days, the
patient has sudden onset of fever, chills, myalgia, and
headache, which rapidly progress to severe illness; a hem-
orrhagic state follows with bleeding from the mucous
membranes and petechiae, associated with thrombocytope-
nia and leukopenia (7). 
CCHFV, like all members of the genus, is a negative-
stranded RNA virus with a tripartite genome consisting of
a small, medium, and large segment encoding the nucleo-
capsid protein; the glycoprotein precursor, which results in
the two envelope glycoproteins G1 and G2; and the puta-
tive RNA-dependent polymerase, respectively (8). 
We report (for the first time in English) the epidemio-
logic characteristics of the disease in Bulgaria. We also
provide the first genetic characterization of the CCHFV
strains circulating in the country from 2002 to 2003 that
caused disease in humans.
Bulgaria is a country of 8 million inhabitants in the
eastern part of the Balkans (Figure 1). CCHF was first rec-
ognized in the country in 1952 and became a reportable
disease in 1953. In 1968, CCHFV was isolated from blood
samples of two patients. Results from serologic investiga-
tions showed that approximately 20% of patients living in
disease-endemic areas who reported a tick bite had anti-
bodies to CCHFV (4). The seropositivity in animals in the
disease-endemic areas can be as high as 50%. Most cases
were reported from Plovdiv and Pazardgik (central
Bulgaria), Haskovo and Kardgali (southeastern Bulgaria),
Shumen (northeastern Bulgaria), and Burgass (eastern
Bulgaria) (4). The most prevalent tick in Bulgaria is Ixodes
ricinus; however CCHFV strains have been isolated from
Hyalomma plumbeum (H. marginatum),  Rhipicephalus
sanguineus, and Boophilus calcaratus (9). 
From 1953 to 1974, 1,105 CCHFV cases were reported
to the Bulgarian Ministry of Health; the fatality rate was
approximately 17%. Of them, 20 cases were nosocomial
infections and 52% were fatal. In 1974, an immunization
program was introduced for medical workers and military
personnel in CCHF-endemic areas. The treatment regimen
consisted of mouse brain preparation inactivated by chlo-
roform, heated at 58°C, and adsorbed on Al(OH)3. The first
two doses were given at day 0 and day 30; a third dose was
given 1 year later, and another dose was given 5 years after
that (10). As a result, between 1975 and 1996, the number
of reported CCHF cases was reduced to 279, with a fatali-
ty rate of 11.4%. No infection was reported from vaccinat-
ed military personnel (11). 
Since 1997, a total of 124 cases occurred in Bulgaria,
27 of them fatal (Table 1). Most patients had been bitten by
a tick; however, a few were infected through direct contact
with CCHF patients. Only the eastern part of the country
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and a second one in northeast. The mean age of patients is
52 years (range 11–79 years). Most patients are men
(74%), probably because they are more frequently exposed
to ticks bites during outdoor activities. The disease occurs
mainly from March to July when ticks are more active. The
main clinical symptoms are fever, malaise, nausea, epis-
taxis, petechiae, and bleeding from the gastrointestinal
tract; the main laboratory findings are leukopenia, throm-
bocytopenia, and elevated transaminase levels. 
To investigate the genetic relationships of the CCHFV
strains circulating recently in Bulgaria, RNA was extract-
ed from cell culture supernatant from six virus isolates.
The virus had been isolated in a Vero E6 cell line from
blood samples taken from CCHF patients who were infect-
ed in 2002 and 2003. The epidemiologic characteristics of
the patients are shown at Table 2. A reverse-transcriptase–
nested polymerase chain reaction (PCR) was applied to
amplify a partial fragment of the S RNA genome segment
by using two sets of primers, F2-R3 and F3-R2 (12).
Purified PCR products were sequenced; the nucleotide
sequences were submitted to the GenBank database and
assigned the accession numbers AY550253–AY550258.
After aligning the obtained Bulgarian CCHFV sequences
with respective ones retrieved from GenBank, we con-
structed a phylogenetic tree with PHYLIP software (13)
(Figure 2). All Bulgarian isolates were found to cluster
together, with a genetic homology of 98.4% to 100% at the
nucleotide level. Identical sequences were obtained from
isolates originating from the same region in the same year. 
The Bulgarian CCHFV strains were found to cluster
with other Balkan strains from Kosovo and Albania, with
a mean genetic difference of 2% and 1.2%, respectively.
All Balkan strains clustered in the same branch with
CCHFV strains from European Russia, such as STV/
HU29223 strain, isolated in 2000 from human blood in
Stavropol (mean genetic difference 2.5%), and ROS/
TI28044, isolated in 2000 from Hyalomma marginatum
ticks in Rostov (mean genetic difference 3.7%) (14). A
“European CCHFV group,” distinct from all others, is evi-
dent. An exception to the European group is the Greek
strain AP92, isolated from R. bursa ticks (5), which forms
an independent clade, which differs from the Bulgarian
strains by 24%. This genetic difference is likely attributa-
ble to the different species of related ticks or to reassort-
ment. Studies on the Greek strain are still in progress; they
will help explain the genetic and pathogenic differences
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Table 1. Distribution of Crimean-Congo hemorrhagic fever cases 
and related deaths in Bulgaria, 1997–2003 
Y  No. of cases  No. of deaths (%)  
1997  20  4 (20) 
1998  15  3 (20) 
1999  5  2 (40) 
2000  10  1 (10) 
2001  18  5 (28) 
2002  56  12 (21) 
2003  14  2 (14) 
 
Table 2. Epidemiologic characteristics of patients whose blood samples yielded Crimean-Congo hemorrhagic fever virus strains  
No. of isolate  Date of disease onset   Sex  Age (y)  Area 
BUL1/03  June 2003  Male  60  Haskovo 
BUL2/03  June 2003  Male  45  Shumen 
BUL3/02  April 2002  Female  62  Shumen 
BUL6/02  June 2002  Male  73  Plovdiv 
BUL9/02  June 2002  Male  23  Shumen 
BUL10/02  August 2002  Male  39  Haskovo 
Figure 2. Phylogenetic tree based on 255-nt fragment from the
S RNA segment, showing the clustering of the sequences
obtained from this study and respective representative Crimean-
Congo hemorrhagic fever virus strains from GenBank database.
Sequences of two other nairoviruses, Dugbe and Hazara, were
included; Hazara virus was used as outgroup. The numbers indi-
cate percentage bootstrap replicates (of 100); values below 70%
are not shown. Horizontal distances are proportional to the
nucleotide differences. The scale bar indicates 10% nucleotide
sequence divergence. Vertical distances are for clarity only.
Sequences used in the analysis are indicated at the tree as:
GenBank accession no., strain, host, country. C.A.R., Central
African Republic.among this strain and respective strains from neighboring
countries. 
Although the genetic divergence among European
strains is low, a great divergence is seen among European
CCHFVstrains and strains from other continents (Asia and
Africa). As the number of CCHFV sequences derived from
the S genome segment is growing, eight distinct clades can
be seen: 1) strain AP92 from Greece; 2) strains from
Senegal, Mauritania, and Iran; 3) strains from Senegal,
Mauritania, and South Africa; 4) strains from Nigeria and
Central African Republic; 5) strain from Uganda; 6) strains
from Central Asia and China; 7) strains from Madagascar,
Iran, and Pakistan; and 8) European strains (Russia,
Albania, Kosovo, and Bulgaria) (Figure 2).
In conclusion, this report shows that the CCHV is
endemic in Bulgaria and causes severe disease in the
whole Balkan Peninsula (except Greece) and that the
Bulgarian CCHFV strains are genetically similar to other
Balkan virus strains (except AP92). CCHFV evolves rela-
tively slowly, which suggests that the great genetic diver-
gence among the strains is not time-dependent. Whether
this divergence is because of the different tick species, the
different geographic location, or any other reason, remains
to be elucidated.
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